Mon, Apr 7, 2025
1- Medical Laboratory Sciences/college of health sciences/Duhok University/Iraq.Duhok
2- Department of Nursing, College of Health and Medical Techniques-Shekhan, Duhok Polytechnic University, Duhok, Iraq ,bizav.naji@dpu.edu.krd
2- Department of Nursing, College of Health and Medical Techniques-Shekhan, Duhok Polytechnic University, Duhok, Iraq ,
Abstract: (348 Views)
Background and objectives: Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. The disease may also affect other parts of the body, including the skin, eyes, lungs, heart, nerves, and blood. Aim and objectives: To evaluate the effect of methotrexate on blood, liver, and renal parameters in Rheumatoid arthritis.
Methods: A six-month cross-sectional study was carried out on 60 consecutive patients of aged 19–70 years with diagnosed Rheumatoid arthritis on methotrexate treatment (10 mg) orally per week. A questionnaire form was taken from participants, and laboratory tests were done on renal and liver function and serological tests (complete blood count, erythrocyte sedimentation rate, glutamic pyruvic transaminase, a glutamic-oxaloacetic transaminase, creatinine, C-reactive protein, and rheumatoid factor as follow-up of drug taking).
Results: At the end of sample collection, age 19–70 years, female: male ratio 1.5:1, while the only significant differences in platelet level were between day one and fourteen of treatment with a P value < 0.05, Glutamic Pyruvic Transaminase (GPT) level was between day one and thirty with a P value < 0.05, and rheumatoid factor level was between day one, fourteen, and day one, thirty with P values of (0.01) and (0.04) respectively which were significant.
Conclusion: The recommended medication for all kinds of rheumatoid arthritis patients is methotrexate, which has had a notable impact on blood, liver, and kidney parameters. These characteristics could be used to track how well this medication works, how safe it is, and to follow up with patients.
Methods: A six-month cross-sectional study was carried out on 60 consecutive patients of aged 19–70 years with diagnosed Rheumatoid arthritis on methotrexate treatment (10 mg) orally per week. A questionnaire form was taken from participants, and laboratory tests were done on renal and liver function and serological tests (complete blood count, erythrocyte sedimentation rate, glutamic pyruvic transaminase, a glutamic-oxaloacetic transaminase, creatinine, C-reactive protein, and rheumatoid factor as follow-up of drug taking).
Results: At the end of sample collection, age 19–70 years, female: male ratio 1.5:1, while the only significant differences in platelet level were between day one and fourteen of treatment with a P value < 0.05, Glutamic Pyruvic Transaminase (GPT) level was between day one and thirty with a P value < 0.05, and rheumatoid factor level was between day one, fourteen, and day one, thirty with P values of (0.01) and (0.04) respectively which were significant.
Conclusion: The recommended medication for all kinds of rheumatoid arthritis patients is methotrexate, which has had a notable impact on blood, liver, and kidney parameters. These characteristics could be used to track how well this medication works, how safe it is, and to follow up with patients.
Keywords: C - reactive protein, Glutamic-Oxaloacetic Transaminase, Glutamic-Pyruvic Transaminase, Hemoglobins, Methotrexate, Rheumatoid
Research Article: Original Paper |
Subject:
Laboratory Sciences
Received: 2024/08/3 | Accepted: 2024/12/31
Received: 2024/08/3 | Accepted: 2024/12/31
References
1. Lee JE, Kim IJ, Cho MS, Lee J. A case of rheumatoid vasculitis involving hepatic artery in early rheumatoid arthritis. Journal of Korean medical science. 2017; 32(7): 1207-10. [View at Publisher] [DOI] [PMID] [Google Scholar]
2. Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, et al. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med Princ Pract. 2018; 27(6): 501-507. [View at Publisher] [DOI] [PMID] [Google Scholar]
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New England Journal of Medicine. 2011; 365(23): 2205-19. [View at Publisher] [DOI] [PMID] [Google Scholar]
4. Chaudhari K, Rizvi S, Syed BA. Rheumatoid arthritis: current and future trends. Nat Rev Drug Discov. 2016; 15(5): 305-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
5. Picerno V, Ferro F, Adinolfi A, Valentini E, Tani C, Alunno A. One year in review: the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 2015; 33(4): 551-8. [View at Publisher] [PMID] [Google Scholar]
6. AlamanosY V. DrososAA. Incidence and Prevalence of Rheumatoid Arthritis, Based on the 1987 American College of Rheumatology Criteria: A Systematic Review. Semin Arthritis Rheum. 2006; 36(3): 182-8. [View at Publisher] [DOI] [PMID] [Google Scholar]
7. Chopra A, Abdel-Nasser A. Epidemiology of rheumatic musculoskeletal disorders in the developing world. Best Practice & Research Clinical Rheumatology. 2008; 22(4): 583-604. [View at Publisher] [DOI] [PMID] [Google Scholar]
8. Singh JA, Saag KG, Bridges SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016; 68(1): 1226‐26. [View at Publisher] [DOI] [PMID] [Google Scholar]
9. Hayashi K, Sada KE, Asano Y, Asano SH, Yamamura Y, Ohashi K, et al. Risk of higher dose methotrexate for renal impairment in patients with rheumatoid arthritis. Sci Rep. 2020; 10(1): 18715.
https://doi.org/10.1038/s41598-020-75655-9 [View at Publisher] [DOI] [PMID] [Google Scholar]
10. Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nature Reviews Rheumatology. 2016; 12(12): 731-42. [View at Publisher] [DOI] [PMID] [Google Scholar]
11. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. Journal of the American College of Cardiology. 2007; 50(1): 40-7. [View at Publisher] [DOI] [PMID] [Google Scholar]
12. Rodríguez-Carrio J, Alperi-López M, López P, Alonso-Castro S, Ballina-García FJ, Suárez A. Red cell distribution width is associated with cardiovascular risk and disease parameters in rheumatoid arthritis. Rheumatology. 2015; 54(4): 641-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
13. Weiss G. Monitoring iron therapy in chronic heart failure. European journal of heart failure. 2013; 15(7): 711-2. [View at Publisher] [DOI] [PMID] [Google Scholar]
14. Al Taii H, Yaqoob Z, Al-Kindi SG. Red cell distribution width (RDW) is associated with cardiovascular disease risk in Crohn's disease. Clinics and research in hepatology and gastroenterology. 2017; 41(4): 490-2. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Annals of the rheumatic diseases. 1996; 55(5): 273. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Gilani ST, Khan DA, Khan FA, Ahmed M. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. J Coll Physicians Surg Pak. 2012; 22(2): 101-4. [View at Publisher] [DOI] [Google Scholar]
17. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. The American journal of medicine. 1991; 90(6): 711-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
18. Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. bmj. 2015; 350. [View at Publisher] [DOI] [PMID] [Google Scholar]
19. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. Clinical drug investigation. 2006; 26: 55-62. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Kim TY, Kim JY, Sohn JH, Lee HS, Bang SY, Kim Y, et al. Assessment of substantial liver fibrosis by real‐time shear wave elastography in methotrexate‐treated patients with rheumatoid arthritis. Journal of Ultrasound in Medicine. 2015; 34(9): 1621-30. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Annals of the rheumatic diseases. 1998; 57(2): 110-3. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU, Bourgeois P, Deray G. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. Rheumatology. 2008; 47(3): 350-4. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Seideman P, Müller-Suur R. Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Annals of the rheumatic diseases. 1993; 52(8): 613-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol. 1995; 22(1): 38-40. [View at Publisher] [PMID] [Google Scholar]
25. Karlsson Sundbaum J, Eriksson N, Hallberg P, Lehto N, Wadelius M, Baecklund E. Methotrexate treatment in rheumatoid arthritis and elevated liver enzymes: A long-term follow-up of predictors, surveillance, and outcome in clinical practice. International journal of rheumatic diseases. 2019; 22(7): 1226-1232. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Ismaili H, Ismaili L, Rexhepi M. Values and Correlations between C-Reactive Protein and Apolipoprotein B after Treatment with Methotrexate at Patients with Rheumatoid Arthritis. Open Access Maced J Med Sci. 2019; 7(8): 1293-1298. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.